AI driven drug discovery The University of Vienna is actively expanding AI-enabled drug discovery capabilities, evidenced by a joint research agreement with Elix to advance AI-driven drug discovery. This presents opportunities to propose AI software platforms, data analytics services, and collaboration models for medicinal chemistry, computational biology, and large-scale testing.

Strategic partnerships The institution emphasizes strategic partnerships and international collaborations, including ties with CEU and Lawrence Berkeley National Laboratory. This signals openness to multi-institution collaborations, sponsorships, and vendor ecosystems around research infrastructure, grant support, and cross-institution data solutions.

Research scale As one of Vienna’s largest employers with 60 locations and a broad research footprint, the university requires scalable IT, data management, and security solutions, as well as enterprise collaboration tools, system integration, and professional services to support teaching, research, and administration at scale.

Awards & visibility Recent high-profile awards across mathematics, chemistry, astrophysics, and quantum optics highlight strong research capabilities and prestige. This can be leveraged to position high-value collaboration proposals, sponsored research, and enterprise software deployments tied to top-tier research outcomes.

Technology stack The tech stack includes AutoCAD, OpenShift, Prometheus, SPSS, Active Directory, VMware, Bitbucket, and Vimeo, indicating demand for software integrations, cloud-native deployments, data analytics, device/identity management, and collaboration tooling across faculties and administration.